Clinical Trial Update: Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating low, intermediate, or high doses of suramin for hormone-refractory prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Suramin (suramin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Prostate Cancer | Phase 3 | Status: COMPLETED